brivaracetam
Trade name: briviact
Approved
Feb 18, 2016
Brivaracetam (UCB 34714, trade name Briviact), the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A), like levetiracetam, but with 20-fold greater affinity. There is some evidence that racetams including levetiracetam and brivaracetam access the luminal side of recycling synaptic vesicles during vesicular endocytosis. They may reduce excitatory neurotransmitter release and enhance synaptic depression during trains of high-frequency activity, such as is believed to occur during epileptic activity. — NCATS
Clinical trial activity
52 trials · 16 clinical orgs · 9 marketing orgs
Earliest trial started Sep 1, 2002 (NCT00401648)
Timeline
2000s
2010s
2020s
- Jun 11, 2021
Zydus Discovery DMCC — Marketing Organization
- Aug 13, 2021
Lupin — Marketing Organization
- Apr 20, 2022
MSN Laboratories — Marketing Organization
- Jun 1, 2022
Annora Pharma — Marketing Organization
- Jun 9, 2022
Sunshine Lake Pharma Co., Ltd. — Marketing Organization
- Jun 13, 2022
Aurobindo Pharma — Marketing Organization
- Jul 12, 2022
Apotex — Marketing Organization
- Aug 12, 2024
Hainan Poly Pharm — Marketing Organization
Indications
Studied for
- Alzheimer Disease · Phase 1/Phase 2
- Brain Neoplasms · Early Phase 1
- Cognitive Dysfunction · Phase 1/Phase 2
- Epilepsies, Partial · Phase 2
- Epilepsy, Absence · Phase 3
- Epilepsy, Reflex · Phase 2/Phase 3
- Healthy Volunteers · Phase 1
- Neuralgia · Phase 3
- Neuralgia, Postherpetic · Phase 2
- Seizures · Phase 3
- Spinal Cord Injuries · Phase 3
- Unverricht-Lundborg Syndrome · Phase 3
Mechanism of action
- Synaptic vesicle glycoprotein 2AMODULATOR
SV2A modulator
Approval history
- approvedFeb 18, 2016
Chemistry & pharmacology
SMILES
CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1- Mol. weight
- 212.2887 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaRivaroxaban ↗
- NCATSU863JGG2IA ↗
- ChEMBLCHEMBL607400 ↗
- ChEMBLCHEMBL198362 ↗
- WikipediaBrivaracetam ↗
Also known as
- 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphas,4r)-
- 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
- (2s)-2-((4r)-2-oxo-4-propylpyrrolidin-1-yl)butanamide
- bay 59-7939
- brivaracetam
- brivaracetam
- brivaracetam
- brivaracetam
- brivaracetam
- brivaracetam
- brivaracetam
- brivaracetam
- brivaracetam
- brivaracetam
- brivaracetam
- briviact
- briviact
- briviact
- briviact
- briviact
- repatoxaban
- ucb34714
- ucb 34714
- ucb 34714
- ucb-34714
- ucb-34714
- ucb-34714
- ucb-34714
- xarelto
- xarelto
- xarelto
- xarelto
- xarelto
- xarelto
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07163572 | N/A | Jan 16, 2025 | RESnTEC, Institute of Research |
| NCT06762743 | Phase 1 | Oct 21, 2024 | Government of China, Nanjing University |
| NCT07163585 | N/A | Aug 1, 2024 | RESnTEC, Institute of Research |
| NCT06315322 | Phase 3 | Jul 10, 2024 | UCB |
| NCT06312566 | Phase 1 | Mar 25, 2024 | UCB |
| NCT05899764 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2023 | University of California, Los Angeles |
| NCT05639946 | Phase 3 | Jan 1, 2023 | University of Minnesota |
| NCT05622370 | Phase 1 | Sep 13, 2022 | Overseas Pharmaceuticals, Ltd. |
| NCT05315947 | Phase 1 | Apr 4, 2022 | UCB |
| NCT05109234 | Phase 3 | Dec 31, 2021 | UCB |
| NCT05029960 | Early Phase 1 (Phase 1) | Dec 31, 2021 | University of Rochester |
| NCT04882540 | Phase 1 | May 19, 2021 | UCB |
| NCT04715646 | Phase 3 | Mar 11, 2021 | UCB |
| NCT04666610 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2020 | UCB |
| NCT04379011 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2020 | Swedish Hospital, University of Minnesota |
| NCT03685630 | Phase 3 | Oct 31, 2018 | UCB |
| NCT03325439 | Phase 2/Phase 3 (Phase 3) | Sep 30, 2018 | UCB |
| NCT03695094 | Phase 1 | Sep 18, 2018 | UCB |
| NCT03580707 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2018 | Comprehensive Epilepsy Care Center for Children & Adults, Pharmaceutical Research Associates, Inc. (PRA), UCB, Utrecht University |
| NCT03405714 | Phase 2 | Jun 1, 2018 | UCB |
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hoosier Cancer Research Network | Academic/Hospital | 28 | 28 | 3 | 2002 |
| UCB | For profit | 15 | 14 | 4 | 2013 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 3 | 0 | 3 | 2014 |
| RESnTEC, Institute of Research | Academic/Hospital | 2 | 2 | 1 | 2024 |
| University of Minnesota | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Comprehensive Epilepsy Care Center for Children & Adults | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Genuine Research Center, Egypt | For profit | 1 | 1 | 1 | 2015 |
| Government of China | Government | 1 | 1 | 1 | 2024 |
| Horus Pharma | For profit | 1 | 0 | 1 | 2015 |
| Nanjing University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Overseas Pharmaceuticals, Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Swedish Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Utrecht University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2015 |
Marketing (13)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Annora Pharma | For profit | MKTG | Jun 1, 2022 |
| Apotex | For profit | MKTG | Jul 12, 2022 |
| Aurobindo Pharma | For profit | MKTG | Jun 13, 2022 |
| Hainan Poly Pharm | For profit | MKTG | Aug 12, 2024 |
| Lupin | For profit | MKTG | Aug 13, 2021 |
| MSN Laboratories | For profit | MKTG | Apr 20, 2022 |
| MSN Laboratories | For profit | SYN | Jun 7, 2022 |
| MSN Laboratories | For profit | SYN | Nov 13, 2025 |
| Sunshine Lake Pharma Co., Ltd. | For profit | MKTG | Jun 9, 2022 |
| UCB | For profit | NDA2 | Feb 18, 2016 |
| UCB | For profit | NDA | Feb 18, 2016 |
| Zydus Discovery DMCC | For profit | SYN | Oct 3, 2022 |
| Zydus Discovery DMCC | For profit | MKTG | Jun 11, 2021 |